ID   WSU-NHL
AC   CVCL_1793
SY   WSU-NHL-1; WSUNHL
DR   CLO; CLO_0009636
DR   EFO; EFO_0006777
DR   CLDB; cl4734
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03470898
DR   BioSample; SAMN03473486
DR   cancercelllines; CVCL_1793
DR   Cell_Model_Passport; SIDM00412
DR   ChEMBL-Cells; CHEMBL3308281
DR   ChEMBL-Targets; CHEMBL2366193
DR   Cosmic; 798674
DR   Cosmic; 909785
DR   Cosmic; 994177
DR   Cosmic; 1086348
DR   Cosmic; 1945197
DR   Cosmic; 2276344
DR   Cosmic-CLP; 909785
DR   DepMap; ACH-001709
DR   DSMZ; ACC-58
DR   DSMZCellDive; ACC-58
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   GDSC; 909785
DR   GEO; GSM380153
DR   GEO; GSM552470
DR   GEO; GSM1035307
DR   GEO; GSM1374992
DR   GEO; GSM1670583
DR   GEO; GSM3150259
DR   IARC_TP53; 21272
DR   LINCS_LDP; LCL-1955
DR   PharmacoDB; WSUNHL_1677_2019
DR   PRIDE; PXD012087
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1793
DR   PubChem_Cell_line; CVCL_1793
DR   Wikidata; Q54994492
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=3143865;
RX   PubMed=7849311;
RX   PubMed=8558920;
RX   PubMed=19278952;
RX   PubMed=20164919;
RX   PubMed=20628145;
RX   PubMed=23292937;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=35839778;
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: MD Anderson Cell Lines Project.
CC   Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11584.
CC   Population: Caucasian.
CC   Doubling time: 57 hours (PubMed=3143865); ~45 hours (DSMZ=ACC-58).
CC   HLA typing: A*02:01,02:01; B*44:02,44:02; C*05:01,07:04 (PubMed=26589293).
CC   Microsatellite instability: Instable (MSI-high) (PubMed=31068700; Sanger).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (Cosmic-CLP).
CC   Omics: Array-based CGH.
CC   Omics: CNV analysis.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: miRNA expression profiling.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0%; Native American=0.04%; East Asian, North=0%; East Asian, South=0.46%; South Asian=3.25%; European, North=71.53%; European, South=24.73% (PubMed=30894373).
CC   Caution: Was originally classified as originating from a follicular lymphoma.
CC   Discontinued: BioIVT/Asterand Bioscience; Catalog number WSU-NHL.
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): Cosmic-CLP; DepMap; DSMZ; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 10,11 (Cosmic-CLP; DepMap; DSMZ)
ST   CSF1PO: 11,13 (PubMed=25877200)
ST   D13S317: 8,10,11 (DepMap; PubMed=25877200)
ST   D13S317: 8,11 (Cosmic-CLP; DSMZ)
ST   D16S539: 10,11,12 (DepMap; PubMed=25877200)
ST   D16S539: 11,12 (Cosmic-CLP; DSMZ)
ST   D18S51: 15
ST   D19S433: 13,14,15,15.2 (PubMed=25877200)
ST   D19S433: 14,15 (DSMZ)
ST   D21S11: 26,30,31,31.2,32.2 (PubMed=25877200)
ST   D21S11: 26,32.2 (DepMap; DSMZ)
ST   D2S1338: 17,23
ST   D3S1358: 14,15
ST   D5S818: 10,11,12 (PubMed=25877200)
ST   D5S818: 11,12 (Cosmic-CLP; DepMap; DSMZ)
ST   D7S820: 10,12
ST   D8S1179: 9,12,13,14 (PubMed=25877200)
ST   D8S1179: 9,14 (DepMap; DSMZ)
ST   FGA: 19,20
ST   Penta D: 9,10,14 (PubMed=25877200)
ST   Penta D: 9,14 (DepMap; DSMZ)
ST   Penta E: 5,11,12,13 (PubMed=25877200)
ST   Penta E: 5,12 (DepMap; DSMZ)
ST   TH01: 6,9 (DSMZ)
ST   TH01: 8,9 (DepMap)
ST   TH01: 9 (Cosmic-CLP; PubMed=25877200)
ST   TPOX: 8,9,10,11 (PubMed=25877200)
ST   TPOX: 9,10 (Cosmic-CLP; DepMap; DSMZ)
ST   vWA: 16 (Cosmic-CLP; DepMap; DSMZ)
ST   vWA: 16,17,19 (PubMed=25877200)
DI   NCIt; C36080; Diffuse large B-cell lymphoma germinal center B-cell type
DI   ORDO; Orphanet_544; Diffuse large B-cell lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   48Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 42
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=3143865; DOI=10.1016/0145-2126(88)90037-9;
RA   Mohamed A.N., Al-Katib A.;
RT   "Establishment and characterization of a human lymphoma cell line
RT   (WSU-NHL) with 14;18 translocation.";
RL   Leuk. Res. 12:833-843(1988).
//
RX   PubMed=7849311; DOI=10.1182/blood.V85.4.893.bloodjournal854893;
RA   Stranks G., Height S.E., Mitchell P., Jadayel D.M., Yuille M.A.R.,
RA   De Lord C., Clutterbuck R.D., Treleaven J.G., Powles R.L.,
RA   Nacheva E., Oscier D.G., Karpas A., Lenoir G.M., Smith S.D.,
RA   Millar J.L., Catovsky D., Dyer M.J.S.;
RT   "Deletions and rearrangement of CDKN2 in lymphoid malignancy.";
RL   Blood 85:893-901(1995).
//
RX   PubMed=8558920;
RA   Dirks W.G., Zaborski M., Jager K., Challier C., Shiota M.,
RA   Quentmeier H., Drexler H.G.;
RT   "The (2;5)(p23;q35) translocation in cell lines derived from malignant
RT   lymphomas: absence of t(2;5) in Hodgkin-analogous cell lines.";
RL   Leukemia 10:142-149(1996).
//
RX   PubMed=19278952; DOI=10.1182/blood-2009-01-202028;
RA   Li C., Kim S.-W., Rai D., Bolla A.R., Adhvaryu S., Kinney M.C.,
RA   Robetorye R.S., Aguiar R.C.T.;
RT   "Copy number abnormalities, MYC activity, and the genetic fingerprint
RT   of normal B cells mechanistically define the microRNA profile of
RT   diffuse large B-cell lymphoma.";
RL   Blood 113:6681-6690(2009).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20628145; DOI=10.1182/blood-2010-05-282780;
RA   Green M.R., Monti S., Rodig S.J., Juszczynski P., Currie T.,
RA   O'Donnell E., Chapuy B., Takeyama K., Neuberg D., Golub T.R.,
RA   Kutok J.L., Shipp M.A.;
RT   "Integrative analysis reveals selective 9p24.1 amplification,
RT   increased PD-1 ligand expression, and further induction via JAK2 in
RT   nodular sclerosing Hodgkin lymphoma and primary mediastinal large
RT   B-cell lymphoma.";
RL   Blood 116:3268-3277(2010).
//
RX   PubMed=23292937; DOI=10.1073/pnas.1205299110;
RA   Zhang J., Grubor V., Love C.L., Banerjee A., Richards K.L.,
RA   Mieczkowski P.A., Dunphy C., Choi W., Au W.Y., Srivastava G.,
RA   Lugar P.L., Rizzieri D.A., Lagoo A.S., Bernal-Mizrachi L., Mann K.P.,
RA   Flowers C.R., Naresh K., Evens A.M., Gordon L.I., Czader M.B., Gill J.I.,
RA   Hsi E.D., Liu Q.-Q., Fan A., Walsh K., Jima D., Smith L.L., Johnson A.J.,
RA   Byrd J.C., Luftig M.A., Ni T., Zhu J., Chadburn A., Levy S.,
RA   Dunson D.B., Dave S.S.;
RT   "Genetic heterogeneity of diffuse large B-cell lymphoma.";
RL   Proc. Natl. Acad. Sci. U.S.A. 110:1398-1403(2013).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//